A5073576936- Bacterial Identification and Susceptibility Testing
- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Antibiotics Pharmacokinetics and Efficacy
- Pneumonia and Respiratory Infections
- Neutropenia and Cancer Infections
- Sepsis Diagnosis and Treatment
- Antimicrobial Resistance in Staphylococcus
- Urinary Tract Infections Management
- Nosocomial Infections in ICU
- Respiratory viral infections research
- Meta-analysis and systematic reviews
- Pneumocystis jirovecii pneumonia detection and treatment
- Clostridium difficile and Clostridium perfringens research
- Antifungal resistance and susceptibility
- Infective Endocarditis Diagnosis and Management
- Streptococcal Infections and Treatments
- Hematological disorders and diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Fungal Infections and Studies
- Influenza Virus Research Studies
- Blood disorders and treatments
- Hematopoietic Stem Cell Transplantation
- Bacterial Infections and Vaccines
- Emergency and Acute Care Studies
Rambam Health Care Campus
2016-2025
Technion – Israel Institute of Technology
2016-2025
Sylhet Agricultural University
2025
World Health Organization
2025
Northumbria University
2024
Biology of Infection
2020
Haifa Medical Center
2019
Philippine General Hospital
2019
University of the Philippines Manila
2019
Wellcome Trust
2019
The polymyxin antibiotics colistin (polymyxin E) and B became available in the 1950s thus did not undergo contemporary drug development procedures. Their clinical use has recently resurged, assuming an important role as salvage therapy for otherwise untreatable gram-negative infections. Since their reintroduction into clinic, significant confusion remains due to existence of several different conventions used describe doses polymyxins, differences formulations, outdated product information,...
Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration antibiotic therapy are limited.This was randomized, multicenter, open-label, noninferiority trial. Inpatients with gram-negative bacteremia, who were afebrile hemodynamically stable for at least 48 hours, randomized receive 7 days (intervention) or 14 (control) covering therapy. Patients uncontrolled focus infection excluded. The primary outcome 90 composite all-cause...
<h3>Importance</h3> Methicillin-resistant<i>Staphylococcus aureus</i>(MRSA) bacteremia is associated with mortality of more than 20%. Combining standard therapy a β-lactam antibiotic has been reduced mortality, although adequately powered randomized clinical trials this intervention have not conducted. <h3>Objective</h3> To determine whether combining an antistaphylococcal effective alone in patients MRSA bacteremia. <h3>Design, Setting, and Participants</h3> Open-label, trial conducted at...